4791 T3D4736 Fludarabine Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. 75607-67-9 30751 C10H13FN5O7P White powder. 260°C 3.53 mg/ml Bioavailability is 55% following oral administration. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. Half Life: 20 hours No indication of carcinogenicity to humans (not listed by IARC). For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen 2014-09-11T05:14:03Z 2026-03-26T21:33:38Z Fludarabine DB01073 true NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1 C10H13FN5O7P InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1 GIUYCYHIANZCFB-FJFJXFQQSA-N 365.2117 365.053662512 Exogenous Solid -2.8 CHEMBL1568 28532 <p>John G. Bauman, Randolph C. Wirsching, &#8220;Process for the preparation of fludarabine or fludarabine phosphate from guanosine.&#8221; U.S. Patent US5602246, issued January, 1992.</p> CHEM003693 DTXSID4039657 NS00003718 {[(2R,3S,4S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid